|
Harold E. "Barry" Selick Ph.D. joined us as Chief Executive Officer in May 2003. Since June 2002 Dr. Selick has been a Venture Partner of Sofinnova Ventures Inc. a venture capital firm. From January 1999 to April 2002 he was Chief Executive Officer of Camitro Corporation a biotechnology company. From 1992 to 1999 he was at Affymax Research Institute the drug discovery technology development center for Glaxo Wellcome plc most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs Inc. and Anergen Inc.. As a staff scientist at Protein Design Labs he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product Zenapax which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California San Francisco. | 